Literature DB >> 10507275

Use patterns for antipsychotic medications in medicaid patients with schizophrenia.

J S McCombs1, M B Nichol, G L Stimmel, J Shi, R R Smith.   

Abstract

OBJECTIVE: We investigated the use patterns for antipsychotic medications generated by Medicaid patients with schizophrenia.
METHOD: Paid claims data from the California Medicaid program (Medi-Cal) were used to identify 2655 patients with schizophrenia. Data from 1987-1996 were used, during which time Medi-Cal maintained prior authorization restrictions on second generation antipsychotic drugs. Prescription records were used to identify 3 patterns of antipsychotic drug use: no drug therapy for over 1 year; delayed onset of antipsychotic drug therapy; and switches in antipsychotic drugs within 1 year. Multiple logistic regression models were used to identify factors affecting these antipsychotic drug use patterns.
RESULTS: Conventional antipsychotic medications account for over 98% of all patient treatment episodes. Over 24% of patients with schizophrenia do not use any antipsychotic medication for periods lasting up to 1 year. Over 24% of treated patients delayed the use of antipsychotic medications at least 30 days. For those patients who did not delay their use of antipsychotic medications, over 47% switched or augmented their initial antipsychotic medication during the first treatment year. Only 11.6% of treated patients achieved 1 year of uninterrupted antipsychotic drug therapy. The mean duration of uninterrupted therapy was 142 days. DISCUSSION: Antipsychotic drug use patterns suggest that conventional antipsychotic medications do not meet the therapeutic needs of patients with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10507275

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  13 in total

1.  A study of treatment outcomes from atypical antipsychotic medications in the Virginia public system of community care.

Authors:  David M Ziegler; Thomas J Peachey
Journal:  Community Ment Health J       Date:  2003-04

2.  Pharmacokinetic and behavioral characterization of a long-term antipsychotic delivery system in rodents and rabbits.

Authors:  Kayla L Metzger; Jody M Shoemaker; Jonathan B Kahn; Christina R Maxwell; Yuling Liang; Jan Tokarczyk; Stephen J Kanes; Meredith Hans; Anthony M Lowman; Nily Dan; Karen I Winey; Neal R Swerdlow; Steven J Siegel
Journal:  Psychopharmacology (Berl)       Date:  2006-11-21       Impact factor: 4.530

3.  Antipsychotic treatment patterns and hospitalizations among adults with schizophrenia.

Authors:  Susan dosReis; Elizabeth Johnson; Donald Steinwachs; Charles Rohde; Elizabeth A Skinner; Maureen Fahey; Anthony F Lehman
Journal:  Schizophr Res       Date:  2008-02-05       Impact factor: 4.939

4.  Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review.

Authors:  Prakash S Masand; Miquel Roca; Martin S Turner; John M Kane
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

5.  Predictors of medication non-adherence in Bulgarian outpatients with schizophrenia.

Authors:  Iglika Vassileva; Vihra Milanova; Turan Asan
Journal:  Community Ment Health J       Date:  2014-01-23

6.  Partial compliance with antipsychotics increases mental health hospitalizations in schizophrenic patients: analysis of a national managed care database.

Authors:  Chris M Kozma; Peter J Weiden
Journal:  Am Health Drug Benefits       Date:  2009-01

7.  Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial.

Authors:  Larry Alphs; Cynthia A Bossie; Jennifer K Sliwa; Yi-Wen Ma; Norris Turner
Journal:  Ann Gen Psychiatry       Date:  2011-04-11       Impact factor: 3.455

8.  Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia.

Authors:  Xinhua S Ren; Lawrence Herz; Shirley Qian; Eric Smith; Lewis E Kazis
Journal:  Neuropsychiatr Dis Treat       Date:  2009-10-12       Impact factor: 2.570

9.  Factors that influence the prescription of antipsychotics for patients with schizophrenia in china.

Authors:  Tian-Mei Si; Liang Shu; Ke-Qing Li; Xie-He Liu; Qi-Yi Mei; Gao-Hua Wang; Pei-Shen Bai; Li-Ping Ji; Xian-Sheng Chen; Cui Ma; Jian-Guo Shi; Hong-Yan Zhang; Hong Ma; Xin Yu
Journal:  Clin Psychopharmacol Neurosci       Date:  2011-12-31       Impact factor: 2.582

10.  An alternative approach to measuring treatment persistence with antipsychotic agents among patients with schizophrenia in the Veterans Health Administration.

Authors:  Xinhua S Ren; Shirley Qian; Lewis E Kazis
Journal:  Neuropsychiatr Dis Treat       Date:  2007-04       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.